摘要
ASCO-GU是泌尿生殖肿瘤诊疗领域的标志性会议。2022 ASCO-GU会议上公布了帕博丽珠单抗辅助治疗延长随访与阿昔替尼/阿维鲁单抗联合新辅助治疗的安全性与有效性结果。在肾癌转移病灶局部治疗、全身系统治疗方案及用药调整等方面也进行了探索。会议还公布了免疫刺激IL-2及PARP抑制剂等新药物的临床研究方案。
ASCO-GU is one of the landmark meetings of urogenital cancer.Within 2022 meeting,the extended follow up result of adjuvant pembrolizumab after nephrectomy in renal cell carcinoma as well as the efficacy and safety of neoadjuvant Axitinib and avelumab for local advanced renal cell carcinoma have been released.There were also explorations in local therapy for oligometastasis,novel combination system therapy and regiments alterations.The further research protocol of immunostimulatory IL-2 cytokine prodrug and PARP inhibitor for metastatic RCC were also disclosed.
作者
曾浩
刘振华
Zeng Hao;Liu Zhenhua(Department of Urology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2022年第4期249-252,共4页
Chinese Journal of Urology
关键词
癌
肾细胞
免疫治疗
靶向治疗
辅助治疗
新辅助治疗
Carcinoma,Renal cell
Immunotherapy
Targeted therapy
Adjuvant therapy
Neoadjuvant therapy
